SCHEMBL1408991

SCHEMBL1408991

C[C@@H](NS(=O)(=O)CC/C=C/Cn1ccc(=O)[nH]c1=O)c1cccc(OCC2CC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1408993 1.00 DUT (1.00) DUT
SCHEMBL1408992 1.00 DUT (1.00) DUT
SCHEMBL1408995 1.00 DUT (1.00) DUT
SCHEMBL1409596 0.87 DUT (1.00) DUT
SCHEMBL1409598 0.87 DUT (1.00) DUT
SCHEMBL1409594 0.87 DUT (1.00) DUT
SCHEMBL1409592 0.87 DUT (1.00) DUT
SCHEMBL1409888 0.86 DUT (1.00) DUT
SCHEMBL1409890 0.86 DUT (1.00) DUT
SCHEMBL1409699 0.86 DUT (1.00) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 US disclosed
US-10889563-B2 Deoxyuridine triphosphatase inhibitors UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2021-01-12 US disclosed
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-08-27 US disclosed
US-10577321-B2 Deoxyuridine triphosphatase inhibitors UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2020-03-03 US disclosed
US-20200039966-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-06 US disclosed
US-20190270719-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS PRESTWICK CHEMICAL, SAS (FR) 2019-09-05 US disclosed
US-10227326-B2 Deoxyuridine triphosphatase inhibitors UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2019-03-12 US disclosed
US-20180155319-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS UNIVERSITY OF SOUTHERN CALIFORNIA 2018-06-07 US disclosed
US-9809571-B2 Deoxyuridine triphosphatase inhibitors UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2017-11-07 US disclosed
WO-2017006270-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2017-01-12 WO disclosed
US-20160039788-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS UNIVERSITY OF SOUTHERN CALIFORNIA 2016-02-11 US disclosed
WO-2014107622-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2014-07-10 WO disclosed
US-8530490-B2 Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-09-10 US disclosed
US-8530490-B2 Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-09-10 US disclosed
EP-2295414-B1 URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2012-09-26 EP disclosed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US disclosed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US disclosed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP disclosed
WO-2009147843-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF 大鵬薬品工業株式会社 (JP) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270719-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885
US-20180155319-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885
US-10889563-B2 Deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885
US-20200039966-A1 URACIL CONTAINING COMPOUNDS UNG, DPYD, DUT DUT 3/4885
US-10227326-B2 Deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885
US-10577321-B2 Deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT DUT 3/4885
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY SNRPB2, SNRPA1, DUT DUT 3/4885
US-20160039788-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.